- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.03. | Optum Rx is reforming how it pays pharmacies | ||
| 21.03. | Delayed CDC meeting on vaccines is rescheduled to April | ||
| 21.03. | AstraZeneca deepens China investment; Editas loses CFO to Dyne | ||
| 21.03. | J&J boosts US manufacturing as big pharma reshores | ||
| 21.03. | Alnylam prices heart drug at premium to rivals | ||
| 20.03. | Alnylam drug gets long-awaited FDA approval in deadly heart disease | ||
| 20.03. | Novartis builds case for new SMA gene therapy | ||
| 20.03. | Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease | ||
| 19.03. | Optum Rx says it will eliminate some prior authorization requirements | ||
| 19.03. | Immunovant claims study success for immune disease drug but holds off on submission | ||
| 19.03. | Cargo shelves cell therapy research and lays off almost all staff | ||
| 18.03. | Sofinnova's latest biotech fund sprouts three new startups | ||
| 18.03. | Prime sets sights on liver, lung disease as next target for its gene editing tech | ||
| 18.03. | Stoke CEO exits; Medicare drug price talks advance | ||
| 18.03. | Duchenne patient dies after receiving Sarepta gene therapy | ||
| 18.03. | Arbor raises $74M amid genetic medicine's funding slump | ||
| 17.03. | Taiho buys Swiss biotech and its ADC tech for $400M | ||
| 17.03. | Orca Bio to seek approval of T cell transplant after positive trial data | ||
| 17.03. | AstraZeneca adds 'in vivo' cell therapy capabilities with EsoBiotech deal | ||
| 17.03. | Latigo raises $150M to get non-opioid pain drugs through key tests | ||
| 17.03. | How biotech and pharma teams are reaching LPI ahead of schedule | ||
| 17.03. | NGS is changing GxP compliance. Will you adapt? | ||
| 14.03. | FDA sets flu shot recommendations without input of outside advisers | ||
| 14.03. | Makary advances to full senate vote; Acelyrin, Pliant adopt 'poison pills' | ||
| 13.03. | MeiraGTx spins Parkinson's, obesity gene therapies into AI startup |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
